Incorporated in 1985, Selan Exploration Technology Ltd is in the business of oil & gas exploration and production
The company operates as a price-taker in a commodity industry where oil prices are set by global benchmarks and gas prices by government mandates. While they possess regulatory licenses for specific fields, these do not provide a durable cost or scale advantage reflected in the modest average ROCE of 11%.
Management has shifted from a debt-free, dividend-paying model to an aggressive reinvestment phase focused on drilling campaigns and inorganic growth. Significant capital is being deployed toward the merger with Antelopus Energy and the acquisition of the Cambay field to scale operations.
The aggressive pivot from a conservative, debt-free dividend payer to a capital-intensive growth vehicle backfired as the merger with the promoter-owned entity resulted in significant capital misallocation. The drilling campaigns in the Cambay basin failed to yield the projected volumes, while global oil prices softened and government gas mandates squeezed margins. The company's transition into a 'black box' of related-party transactions and inter-corporate loans drained the cash reserves that once protected shareholders, leaving the firm with stagnant production and a depleted treasury.
RichFakir rates Antelopus Selan Energy Ltd's business quality as mediocre — 43/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Antelopus Selan Energy Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Antelopus Selan Energy Ltd is: Not rated. A mediocre business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Antelopus Selan Energy Ltd's fair value is about ₹234 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →